Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...
Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback